'Treatment experienced' presentation slideshows

New Treatment for HCV G4 Towards an End to HCV Epidemic in Egypt

New Treatment for HCV G4 Towards an End to HCV Epidemic in Egypt. Several potential innovative drug targets in HCV. NS3. NS2. NS5A. c. NS5B. E1. E2.

632 views • 40 slides

New Treatment for HCV G4 Towards an End to HCV Epidemic in Egypt

New Treatment for HCV G4 Towards an End to HCV Epidemic in Egypt. Several potential innovative drug targets in HCV. NS3. NS2. NS5A. c. NS5B. E1. E2.

403 views • 40 slides

Treatment for HCV Infection Is Better Than Ever; Are You and Your Patients Ready?

Treatment for HCV Infection Is Better Than Ever; Are You and Your Patients Ready?. 2 Second-Generation DAA Agents Approved by the FDA. Recommendations for Testing, Managing, and Treating Hepatitis C.

212 views • 13 slides

Buy LediHep Tablets Online price from India

Treat Chronic Hepatitis C with Emedkit. BUY LEDIHEP TABLETS PRICE FROM INDIA is very Affordable for the generic medicines to cure Hepatitis C. Connect to Emedkit the best GENERIC MEDICINE SUPPLIER and get best Ledihep Tablet Price in India.

126 views • 12 slides

Glecaprevir - Pibrentasvir in GT 1- 6 with Renal Disease EXPEDITION-4

268 views • 11 slides

Sofosbuvir-Velpatasvir- Voxilaprevir in NS5A-Experienced GT 1-6 POLARIS-1

277 views • 11 slides

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 TURQUOISE-II

220 views • 11 slides

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A1444-040 Trial

330 views • 10 slides

Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4

110 views • 10 slides

Elbasvir + Grazoprevir + /- RBV in GT 1 Cirrhotics & Null Responders C-WORTHY

248 views • 9 slides

Simeprevir in HIV Coinfection, GT-1 C212 Trial

221 views • 9 slides

3 D (Paritaprevir -Ritonavir -Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-II

Phase 3. Treatment Experienced. 3 D (Paritaprevir -Ritonavir -Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-II. Zeuzem S, et al. N Engl J Med. 2014;370:1604-14. 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1 SAPPHIRE -II: Study Design.

238 views • 9 slides

3D (Paritaprevir-Ritonavir- Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II

Phase 3. Treatment Experienced. 3D (Paritaprevir-Ritonavir- Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II. Andreone P, et al. Gastroenterology. 2014;147:359-65. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + /- RBV in GT1b PEARL - II: Study Design.

252 views • 9 slides

The Lancet. Infectious diseases. June 2015, PMID: 25863559

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. The Lancet. Infectious diseases. June 2015, PMID: 25863559.

97 views • 8 slides

3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 Study M12-999

191 views • 8 slides

Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation

262 views • 8 slides

3 D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 TURQUOISE-I

233 views • 7 slides

Sofosbuvir-Ledipasvir +/- Ribavirin in GT-1 LONESTAR Trial

72 views • 7 slides

Ledipasvir + Sofosbuvir +/- Ribavirin in GT 1-3 ELECTRON 2

356 views • 6 slides

Background

Aggregation, Modeling and Prediction of HIV Antiviral Efficacy Data from the Last 10 Years of Published Clinical Trials (AMPLY)-Part II: Meta-Data Analysis of Full Time Course Response Rates Joannellyn Chiu (1), Xiaohua Gong (1), Mark Lovern (1), Roberto Gomeni (2)

88 views • 1 slides